PMC:7565665 / 70183-71436 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T496","span":{"begin":810,"end":820},"obj":"Disease"},{"id":"T497","span":{"begin":1031,"end":1041},"obj":"Disease"}],"attributes":[{"id":"A496","pred":"mondo_id","subj":"T496","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A497","pred":"mondo_id","subj":"T497","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Another reason to explore treatments that restore the CFTR-autophagy function to treat exacerbations is that the current first-line treatment for exacerbations usually includes antibiotics [4,173,210,212,213]. In situations where patients experience severe exacerbations, they are often hospitalized and given powerful intravenous (IV) antibiotics [4,31,173,176]. This is part of what plays into the exorbitant costs associated with recurrent exacerbations. When looking specifically at exacerbations requiring hospitalization and IV-antibiotics, the cost is USD 36,319 per exacerbation for patients [176]. This frequent use of antibiotics in both the out-patient and in-patient treatment of exacerbations causes bacteria to develop MDR, which poses a significant issue for patients as the treatment of future infections becomes more difficult [151,214,215]. In fact, many pathogens that cause exacerbations have been found to have MDR [214,215]. As more bacteria demonstrate MDR, more powerful antibiotics are needed to fight off infections, but these powerful antibiotics can have negative side effects. As such, researchers have begun investigating the potential of targeting the autophagy pathway to fight off the MDR bacteria causing exacerbations."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T806","span":{"begin":54,"end":58},"obj":"http://purl.obolibrary.org/obo/PR_000001044"},{"id":"T807","span":{"begin":713,"end":721},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_2"},{"id":"T808","span":{"begin":750,"end":751},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T809","span":{"begin":955,"end":963},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_2"},{"id":"T810","span":{"begin":1222,"end":1230},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_2"}],"text":"Another reason to explore treatments that restore the CFTR-autophagy function to treat exacerbations is that the current first-line treatment for exacerbations usually includes antibiotics [4,173,210,212,213]. In situations where patients experience severe exacerbations, they are often hospitalized and given powerful intravenous (IV) antibiotics [4,31,173,176]. This is part of what plays into the exorbitant costs associated with recurrent exacerbations. When looking specifically at exacerbations requiring hospitalization and IV-antibiotics, the cost is USD 36,319 per exacerbation for patients [176]. This frequent use of antibiotics in both the out-patient and in-patient treatment of exacerbations causes bacteria to develop MDR, which poses a significant issue for patients as the treatment of future infections becomes more difficult [151,214,215]. In fact, many pathogens that cause exacerbations have been found to have MDR [214,215]. As more bacteria demonstrate MDR, more powerful antibiotics are needed to fight off infections, but these powerful antibiotics can have negative side effects. As such, researchers have begun investigating the potential of targeting the autophagy pathway to fight off the MDR bacteria causing exacerbations."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T15814","span":{"begin":177,"end":188},"obj":"Chemical"},{"id":"T63851","span":{"begin":332,"end":334},"obj":"Chemical"},{"id":"T174","span":{"begin":336,"end":347},"obj":"Chemical"},{"id":"T66577","span":{"begin":531,"end":533},"obj":"Chemical"},{"id":"T99338","span":{"begin":534,"end":545},"obj":"Chemical"},{"id":"T70909","span":{"begin":628,"end":639},"obj":"Chemical"},{"id":"T83059","span":{"begin":733,"end":736},"obj":"Chemical"},{"id":"T72009","span":{"begin":932,"end":935},"obj":"Chemical"},{"id":"T3847","span":{"begin":976,"end":979},"obj":"Chemical"},{"id":"T45661","span":{"begin":995,"end":1006},"obj":"Chemical"},{"id":"T7261","span":{"begin":1062,"end":1073},"obj":"Chemical"},{"id":"T16389","span":{"begin":1218,"end":1221},"obj":"Chemical"}],"attributes":[{"id":"A78190","pred":"chebi_id","subj":"T15814","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A12995","pred":"chebi_id","subj":"T63851","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A21965","pred":"chebi_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A97311","pred":"chebi_id","subj":"T66577","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A35123","pred":"chebi_id","subj":"T99338","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A48494","pred":"chebi_id","subj":"T70909","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A75952","pred":"chebi_id","subj":"T83059","obj":"http://purl.obolibrary.org/obo/CHEBI_53218"},{"id":"A93569","pred":"chebi_id","subj":"T72009","obj":"http://purl.obolibrary.org/obo/CHEBI_53218"},{"id":"A14689","pred":"chebi_id","subj":"T3847","obj":"http://purl.obolibrary.org/obo/CHEBI_53218"},{"id":"A56009","pred":"chebi_id","subj":"T45661","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A36510","pred":"chebi_id","subj":"T7261","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A64164","pred":"chebi_id","subj":"T16389","obj":"http://purl.obolibrary.org/obo/CHEBI_53218"}],"text":"Another reason to explore treatments that restore the CFTR-autophagy function to treat exacerbations is that the current first-line treatment for exacerbations usually includes antibiotics [4,173,210,212,213]. In situations where patients experience severe exacerbations, they are often hospitalized and given powerful intravenous (IV) antibiotics [4,31,173,176]. This is part of what plays into the exorbitant costs associated with recurrent exacerbations. When looking specifically at exacerbations requiring hospitalization and IV-antibiotics, the cost is USD 36,319 per exacerbation for patients [176]. This frequent use of antibiotics in both the out-patient and in-patient treatment of exacerbations causes bacteria to develop MDR, which poses a significant issue for patients as the treatment of future infections becomes more difficult [151,214,215]. In fact, many pathogens that cause exacerbations have been found to have MDR [214,215]. As more bacteria demonstrate MDR, more powerful antibiotics are needed to fight off infections, but these powerful antibiotics can have negative side effects. As such, researchers have begun investigating the potential of targeting the autophagy pathway to fight off the MDR bacteria causing exacerbations."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1734","span":{"begin":54,"end":58},"obj":"Gene"},{"id":"1735","span":{"begin":230,"end":238},"obj":"Species"},{"id":"1736","span":{"begin":591,"end":599},"obj":"Species"},{"id":"1737","span":{"begin":656,"end":663},"obj":"Species"},{"id":"1738","span":{"begin":671,"end":678},"obj":"Species"},{"id":"1739","span":{"begin":774,"end":782},"obj":"Species"},{"id":"1740","span":{"begin":810,"end":820},"obj":"Disease"},{"id":"1741","span":{"begin":1031,"end":1041},"obj":"Disease"}],"attributes":[{"id":"A1734","pred":"tao:has_database_id","subj":"1734","obj":"Gene:1080"},{"id":"A1735","pred":"tao:has_database_id","subj":"1735","obj":"Tax:9606"},{"id":"A1736","pred":"tao:has_database_id","subj":"1736","obj":"Tax:9606"},{"id":"A1737","pred":"tao:has_database_id","subj":"1737","obj":"Tax:9606"},{"id":"A1738","pred":"tao:has_database_id","subj":"1738","obj":"Tax:9606"},{"id":"A1739","pred":"tao:has_database_id","subj":"1739","obj":"Tax:9606"},{"id":"A1740","pred":"tao:has_database_id","subj":"1740","obj":"MESH:D007239"},{"id":"A1741","pred":"tao:has_database_id","subj":"1741","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Another reason to explore treatments that restore the CFTR-autophagy function to treat exacerbations is that the current first-line treatment for exacerbations usually includes antibiotics [4,173,210,212,213]. In situations where patients experience severe exacerbations, they are often hospitalized and given powerful intravenous (IV) antibiotics [4,31,173,176]. This is part of what plays into the exorbitant costs associated with recurrent exacerbations. When looking specifically at exacerbations requiring hospitalization and IV-antibiotics, the cost is USD 36,319 per exacerbation for patients [176]. This frequent use of antibiotics in both the out-patient and in-patient treatment of exacerbations causes bacteria to develop MDR, which poses a significant issue for patients as the treatment of future infections becomes more difficult [151,214,215]. In fact, many pathogens that cause exacerbations have been found to have MDR [214,215]. As more bacteria demonstrate MDR, more powerful antibiotics are needed to fight off infections, but these powerful antibiotics can have negative side effects. As such, researchers have begun investigating the potential of targeting the autophagy pathway to fight off the MDR bacteria causing exacerbations."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T927","span":{"begin":54,"end":58},"obj":"http://purl.obolibrary.org/obo/GO_0005260"},{"id":"T928","span":{"begin":59,"end":68},"obj":"http://purl.obolibrary.org/obo/GO_0016236"},{"id":"T929","span":{"begin":59,"end":68},"obj":"http://purl.obolibrary.org/obo/GO_0006914"},{"id":"T930","span":{"begin":1183,"end":1192},"obj":"http://purl.obolibrary.org/obo/GO_0016236"},{"id":"T931","span":{"begin":1183,"end":1192},"obj":"http://purl.obolibrary.org/obo/GO_0006914"}],"text":"Another reason to explore treatments that restore the CFTR-autophagy function to treat exacerbations is that the current first-line treatment for exacerbations usually includes antibiotics [4,173,210,212,213]. In situations where patients experience severe exacerbations, they are often hospitalized and given powerful intravenous (IV) antibiotics [4,31,173,176]. This is part of what plays into the exorbitant costs associated with recurrent exacerbations. When looking specifically at exacerbations requiring hospitalization and IV-antibiotics, the cost is USD 36,319 per exacerbation for patients [176]. This frequent use of antibiotics in both the out-patient and in-patient treatment of exacerbations causes bacteria to develop MDR, which poses a significant issue for patients as the treatment of future infections becomes more difficult [151,214,215]. In fact, many pathogens that cause exacerbations have been found to have MDR [214,215]. As more bacteria demonstrate MDR, more powerful antibiotics are needed to fight off infections, but these powerful antibiotics can have negative side effects. As such, researchers have begun investigating the potential of targeting the autophagy pathway to fight off the MDR bacteria causing exacerbations."}

{"project":"LitCovid-sentences","denotations":[{"id":"T367","span":{"begin":0,"end":209},"obj":"Sentence"},{"id":"T368","span":{"begin":210,"end":363},"obj":"Sentence"},{"id":"T369","span":{"begin":364,"end":457},"obj":"Sentence"},{"id":"T370","span":{"begin":458,"end":606},"obj":"Sentence"},{"id":"T371","span":{"begin":607,"end":858},"obj":"Sentence"},{"id":"T372","span":{"begin":859,"end":946},"obj":"Sentence"},{"id":"T373","span":{"begin":947,"end":1105},"obj":"Sentence"},{"id":"T374","span":{"begin":1106,"end":1253},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Another reason to explore treatments that restore the CFTR-autophagy function to treat exacerbations is that the current first-line treatment for exacerbations usually includes antibiotics [4,173,210,212,213]. In situations where patients experience severe exacerbations, they are often hospitalized and given powerful intravenous (IV) antibiotics [4,31,173,176]. This is part of what plays into the exorbitant costs associated with recurrent exacerbations. When looking specifically at exacerbations requiring hospitalization and IV-antibiotics, the cost is USD 36,319 per exacerbation for patients [176]. This frequent use of antibiotics in both the out-patient and in-patient treatment of exacerbations causes bacteria to develop MDR, which poses a significant issue for patients as the treatment of future infections becomes more difficult [151,214,215]. In fact, many pathogens that cause exacerbations have been found to have MDR [214,215]. As more bacteria demonstrate MDR, more powerful antibiotics are needed to fight off infections, but these powerful antibiotics can have negative side effects. As such, researchers have begun investigating the potential of targeting the autophagy pathway to fight off the MDR bacteria causing exacerbations."}